Table 2.
The role of miR-484 in Non-Cancerous Diseases.
| Disease | Species and tissue or cell type | Alteration of miR-484 expression | Method for miR-484detection | Target gene | Method for target validation | Biological function | Sample size in clinical studies | Ref | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MI/R | Rat heart tissue | down-regulation | qRT-PCR | SMAD7 | qRT-PCR and the luciferase reporter gene assay | Anti-inflammatory Anti-apoptotic Protection of mitochondria |
N/A | (26) |
| 2 | MI/R | Mouse heart tissue | down-regulation | qRT–PCR | Fis-1 | qRT-PCR, WB and Luciferase assays | Inhibit mitochondria fission | N/A | (48) |
| 3 | MI/R | Human BS (Japan) |
up-regulation | qRT–PCR | N/A | N/A | High exercise capacity after MI/R | AMI patients(n=20) and healthy control subjects (n=5) | (49) |
| 4 | AS | Human postbifurcation carotid plaques (Pennsylvania) |
up-regulation | Affymetrix GeneChip microRNA Array and qRT–PCR | DACH1 | N/A | Associated with plaque fragility after carotid bifurcation | symptomatic (n=9) and asymptomatic patients (n=9) with carotid stenosis | (73) |
| 5 | AS | Human BS (American) |
up-regulation | qRT–PCR | N/A | N/A | Induction of endothelial dysfunction | patients with CAD (n = 56) and HCs (n = 10) | (31) |
| 6 | AS | Human plasma and EPCs of patients with CAD | up-regulation | smRNA-seq qRT–PCR |
N/A | N/A | Cannot inhibit VEGF expression and EPC activity | N/A | (56) |
| 7 | SIC | Rat cardiomyocytes (H9c2) | up-regulation | qRT–PCR | YAP1 | qRT-PCR, WB and the luciferase reporter gene assay | Promoted cell viability Decreased apoptosis and inflammation |
N/A | (34) |
| 8 | DIC | Rat cardiomyocytes (H9c2) | down-regulation | qRT–PCR | LINC00339 | the luciferase reporter gene assay | Promot proliferation Inhibit apoptosis |
N/A | (74) |
| 9 | 16p13.11 microduplication syndrome | Mouse cortical progenitor Mouse cortical neuron |
up-regulation | qRT–PCR | PCDH19 | the luciferase reporter gene assay | promotes neurogenesis | N/A | (20) |
| 10 | Cerebral injury-related diseases | Mouse brain tissue | down-regulation | qRT–PCR | BCL2L13 | the luciferase reporter gene assay | Inhibit apoptosis | N/A | (25) |
| 11 | Psoriasis | Human epidermal keratinocyte (China) | down-regulation | LncRNA and mRNA microarray and construction of the competing endogenous RNA (ceRNA) network | MLH3, lncSNX10-2:8, lnc-MNX1-5:1, lnc-1QCD-1:1 |
N/A | N/A | 15 age-matched and gender-matched (n=15) healthy skin control 15 patients with progressive psoriasis vulgaris (n=15) |
(53) |
| up-regulation | DCTN3 Lnc-AGXT2L1-2:2 |
||||||||
| 12 | Hepatitis B virus | Human dendritic cells (India) |
up-regulation | qRT–PCR Unsupervised hierarchical clustering and principal component analyses | N/A | N/A | N/A | HBV infection and liver disease namely, immune active (IA; n = 20); low replicative (LR; n = 20); HBeAg negative (n = 20); acute viral hepatitis (AVH, n = 20) and healthy controls (n = 20). | (75) |
| 13 | Hepatitis C virus | Human BS (Egyptian) | up-regulation | qRT–PCR | N/A | N/A | N/A | Egyptian patients with HCV liver fibrosis(n=47), HCV-cirrhosis(n=40), HCV- HCC(n=41) Healthy controls(n=40) |
(76) |
| 14 | Dengue | Vero cells | down-regulation | qRT–PCR | DENV RNA | qRT–PCR The RNAhybrid program MicroInspector |
virus replication | Vero cells (CCL-81) Mosquito C6/36 HT cells |
(77) |
| 15 | Tuberculosis | Human serum-derived exosomes (Iran) | up-regulation | qRT–PCR | N/A | N/A | N/A | Patients with TB(n=25) Healthy controls with a negative history of TB (n=25) |
(78) |
| 16 | Leprosy | Human leprosy skin lesions (Brazil) | up-regulation | qRT–PCR | FASN | The genes selected from the miRNA/mRNA analysis were submitted to pathway enrichment analysis by using the ReactomeFIViz plugin from the Cytoscape software | N/A | Leprosy lesions (TT = 10, BT = 10, BB = 10, BL = 10, LL = 4, R1 = 14, and R2 = 10) Healthy control (n = 9) |
(79) |
BS, Blood sample; CAD, coronary artery disease; EPC, endothelial progenitor cell; IA, immune active; LR, low replicative; AVH, acute viral hepatitis; TT, tuberculoid; BT, borderline tuberculoid; BB, borderline borderline; BL, borderline lepromatous; LL, lepromatous; R1, type 1 reaction; R2, type 2 reaction.
NA, Not answered.